Computational Drug Safety & PKPD Modeling - software & AI news

Daily news on software, AI, and companies shaping computational drug safety & pkpd modeling.

Showing 29 results
Press release cover image

Oct 1, 2026

PumasAI Brings AI, Scientific Machine Learning and Advanced Pharmacometric Research to ACoP 2026

Pre-conference AI in pharmacometrics workshop and four scientific poster presentations highlight PumasAI’s presence at the American Conference on PharmacometricsNATIONAL HARBOR, Md. and DOVER, Del.— PumasAI,an AI-powered clinical pharmacology and pharmacometrics company transforminghow pharmaceutical teams work, today announced its scientific program for theAmerican Conference on Pharmacometrics (ACoP 2026), taking placeOctober 11-14, 2026, at the Gaylord National Resort & Convention Center
Press release cover image

Sep 29, 2026

GATC Health's Derisq Named One of The Scientist's 2026 Top Innovations

GATC’s Derisq™, the definitive AI report for predictive risk intelligence, named a Top Emerging Startup Technology by independent panel of life sciences experts at the esteemed publication. IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- GATC Health Corp (“GATC”), a tech-bio company applying artificial intelligence and multiomics to de-risk and accelerate drug discovery and development, today announced that its Derisq™ AI report has been named one of The Scientist’s 2026 Top Innovations, re
Press release cover image

Sep 23, 2026

Corealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation Development

Combining formulation expertise and predictive modeling to make smarter development decisions earlier and reduce clinical development risk.LAVAL, Quebec--(BUSINESS WIRE)--Corealis Pharma (“Corealis”) and PhinC Group (“PhinC”) have announced a strategic collaboration to integrate physiologically based biopharmaceutics modeling (PBBM) and physiologically based pharmacokinetic (PBPK) modeling directly into oral solid dosage form development.The collaboration brings together Corealis’ formulation an
Press release cover image

Sep 18, 2026

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

Agency will use the software platform to support modern cosmetic safety assessment through integrated exposure and toxicity modeling.RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to su
Press release cover image

Sep 17, 2026

Inductive Launches Beacon-2, Making Human Dose Computable for Chemists and AI Agents Across Biopharma

Chemists can now estimate which compounds will have the best human dose before making them in the labNEW YORK, Sept. 17, 2026 /PRNewswire/ -- Inductive launched Beacon-2 today, a system that predicts the efficacious human dose of a small molecule directly from its chemical structure.Dose is the number that decides whether a compound can become a drug. It accounts for both how potent a molecule is and what the body does to it. A drug that works at a lower dose also carries less risk of off-target
Press release cover image

Sep 17, 2026

Quotient Sciences Proprietary AI-Enhanced Solution Optimizes Formulation in Clinical Study

— Proprietary algorithm optimized tablet composition and dose level for clinical study in healthy participants —— Interim results suggest significant potential for developing optimized formulations with fewer clinical rounds —NOTTINGHAM, England, Sept. 17, 2026 /PRNewswire/ -- Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), today reported interim results from a clinical study in which a proprietary artificial intelligence (AI) algorit
Press release cover image

Sep 14, 2026

GATC Health Joins Critical Path Institute’s New Approach Methodologies Developer Coalition to Advance AI-Enabled Regulatory Science

GATC to contribute AI-native, in silico drug discovery and predictive modeling expertise and insights to collaborative effort advancing the validation, qualification and adoption of human-relevant drug development tools C-Path is an independent nonprofit public-private partnership advancing regulatory science and accelerating drug development through collaboration with the FDA, industry, and researchers GATC executives to attend C-Path’s 2026 Global Impact Conference September 15–16 in Washingto
Press release cover image

Sep 8, 2026

Amino Minder Brings Real Pharmacokinetic Modeling to Peptide and GLP-1 Tracking, Now Live on the Web -- Android App Coming Soon

New tracker goes beyond dose logging to model estimated plasma levels over time, including downstream hormone cascades for GH-secretagogue stacksKINGMAN, Ariz., Sept. 8, 2026 /PRNewswire/ -- Baya Lobo LLC today announced the web launch of Amino Minder (aminominder.com), a peptide, GLP-1, TRT, and HRT protocol tracker built around a feature no competing app currently claims: a real pharmacokinetic (PK) engine that estimates and graphs a user's plasma level for each tracked compound over time, rat
Press release cover image

Sep 3, 2026

EpiVax lance des modèles optimisés par l'IA pour la prédiction de l'immunogénicité

PROVIDENCE, Rhode Island, 3 septembre 2026 /PRNewswire/ -- EpiVax, Inc. a le plaisir d'annoncer la mise à disposition de nouvelles fonctionnalités basées sur l'intelligence artificielle pour ISPRI™, sa plateforme in silico exclusive destinée à l'évaluation du risque d'immunogénicité des produits biothérapeutiques. Cette version présente une version mise à jour du modèle JanusMatrix™, un score d'immunogénicité affiné et ajusté en fonction des tolérances, ainsi qu'un modèle amélioré de prédiction
Press release cover image

Sep 2, 2026

EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

PROVIDENCE, R.I., Sept. 2, 2026 /PRNewswire/ -- EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the immunogenicity risk of biotherapeutics. The release introduces an updated JanusMatrix™ model, a refined tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody (ADA) prediction model designed to provide deeper insight into immunogenicity risk. For decades, EpiVax has pioneered computational i
A glass vial with a colorful drug compound on a lab bench

Aug 21, 2026

DeepCyte Launches Single-Cell Metabolomic Reference Atlas of Drug Toxicity Mechanisms

DeepCyte has introduced the DeeTox Atlas, a pioneering single-cell metabolomic reference designed to elucidate drug toxicity mechanisms. This initiative is set to engage in pilot programs with leading pharmaceutical firms in the near future.The DeeTox Atlas serves as a foundational dataset derived from two separate single-cell metabolomics studies, encompassing around 100 toxic compounds, 300,000 individual cells, and approximately 500 metabolites per cell. The data includes over 3,000 single-ce
Press release cover image

Aug 19, 2026

PumasAI Launches New Clinical Pharmacology Webinar Series Showcasing End-to-End AI-Powered PK Analysis

Four-part PumasCP End-to-End series demonstrates howclinical pharmacology teams can move from raw data to regulatory-readyreporting within a single reproducible environmentPumasAI, an AI-powered clinical pharmacology andpharmacometrics company transforming how pharmaceutical teams work, todayannounced the launch of PumasCP End-to-End, a new four-part educational webinarseries designed to help clinical pharmacology professionals streamlinepharmacokinetic (PK) analyses through a single reproducibl